Pharmaceutical preparation containing imatinib mesylate and preparation method thereof
A technology for imatinib mesylate and pharmaceutical preparations, applied in the field of pharmaceutical preparations, can solve the problems of unsuitable α crystal form and difficult medicinal use of imatinib mesylate, and achieves reduced types of excipients and high safety Effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0030] The preparation of embodiment 1~3 different wetting agent tablet
[0031] The composition of table 1 tablet (1000 pieces)
[0032] Element
Example 1
Example 2
Example 3
Imatinib mesylate
120g
120
120
microcrystalline cellulose
55g
55
55
Crospovidone
40g
40
40
silica
3g
3g
3g
Magnesium stearate
2g
2g
2g
Opadry
6.6g
6.6g
6.6g
lubricant
50% ethanol
75% ethanol
ethanol
[0033] 1.1 Preparation
[0034] Mix the pretreated imatinib mesylate and internal pharmaceutical excipients in a wet granulation pot, then granulate with a wetting agent, then dry and granulate, add external excipients and mix, then compress into tablets, package Clothes.
[0035] 1.2 Evaluation
[0036] Method: Chinese Pharmacopoeia 2010 Edition II XC Second Method Paddle Method
[0037] Medium: 900ml of hydrochloric acid solution with pH 1....
Embodiment 8-10
[0059] Adopt the preparation method of embodiment 1-3, wherein wetting agent is 75% ethanol
[0060] Element
Example 8
Example 9
Example 10
Imatinib mesylate
120g
120g
120g
microcrystalline cellulose
60.3g
49.5g
35.3g
Crospovidone
33g
44g
55g
silica
4.5g
3.3g
7.5g
Magnesium stearate
1.1g
2.2g
1.1g
Opadry
1.1g
1.1g
1.1g
lubricant
75% ethanol
75% ethanol
75% ethanol
[0061] Gained preparation dissolution rate result is as follows:
[0062] Table 5 Dissolution evaluation results
[0063]
[0064] Result: the dissolution results of the above examples show that the dissolution effects of the preparation examples of the present invention are stable and have good reproducibility.
experiment example 1
[0065] Experimental example 1, stability test
[0066] In order to verify whether the preparation containing the α crystal form in the present invention will transform into the β crystal form in a long-term storage environment, the inventor prepared 3 batches of samples using the prescription and preparation process of Example 2 and Example 9, respectively named For samples 2-1, 2-2, 2-3 and 9-1, 9-2, 9-3, samples were taken to detect the transformation of the preparation crystal form in different environments.
[0067] Table 6 Crystal Form Stability Monitoring (25±2°C, RH=60%±15%)
[0068]
[0069]
[0070] Table 7 Crystal Form Stability Monitoring (45±2°C, RH=75%±5%)
[0071]
[0072] Note: The criterion for distinguishing whether the crystal is transformed is that at least one diffraction peak deviates from the normal error by 0.2°. If the marker peak (diffraction peak with 2θ of 4.9) is missing, it can be determined that the α crystal form has undergone transform...
PUM
Property | Measurement | Unit |
---|---|---|
particle size | aaaaa | aaaaa |
density | aaaaa | aaaaa |
density | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
![application no application](https://static-eureka-patsnap-com.libproxy1.nus.edu.sg/ssr/23.2.0/_nuxt/application.06fe782c.png)
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap